Skip to main content
Home / News and Insights / News / BDB Pitmans advises Renalytix AI on £14 million placing
09 August 2019

BDB Pitmans advises Renalytix AI on £14 million placing

BDB Pitmans is proud to have advised clinical diagnostics company, Renalytix AI Plc (Renalytix), as it raised £14 million through a secondary fundraise. The placing was in high demand from both existing and new shareholders, with Renalytix placing 5.6 million shares at a price of 250 pence each.

Renalytix is a developer of artificial intelligence enabled clinical decision support solutions for kidney disease, one of the most common and costly chronic medical conditions globally. Renalytix solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.

The BDB Pitmans team advising on the transaction was led by partner Nick McCarthy, who was supported by legal director Andrew McGlashan and solicitor Caroline Carter. Stifel Nicolaus Europe Limited and N+1 Singer acted as joint bookrunners in relation to the placing.

Nick McCarthy, partner at BDB Pitmans comments:

‘We are delighted to have advised this new client on a very successful fundraise.’

Related Articles

London and Cambridge Offices

London Westminster
50 Broadway, London

50/60 Station Road

Reading and Southampton Offices

Reading, The Anchorage
34 Bridge Street Berkshire
Reading RG1 2LU

Grosvenor House, Grosvenor Square
Southampton SO15 2BE

Follow us

  • Pay my invoice
  • Lexcel

© BDB Pitmans 2019. 50 Broadway, London, SW1H 0BL - T +44 (0)345 222 9222